Low Apremilast Persistence May Hinder Remission, Recovery Among Patients with PsA
Results demonstrated a low persistence rate for apremilast among patients with PsA, highlighting a notable barrier to treatment success.
Samir Haddad Carmel Medical Center Israeli National Healthcare Drug Plan Clalit Health Services National Psoriasis Foundation Israeli National Healthcare Drug
Source: hcplive.com